 |
TSO3: an additional sale in CanadaOctober 23, 2007Québec City, October 23, 2007 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces the sale of a 125L Ozone Sterilizer to a Canadian hospital, which was awarded following a tender.This hospital’s tender was designed to answer a need for another low temperature sterilizer, as well as to comply with the Canadian regulations that pursue the goal of reducing the emission of ethylene oxide, a toxic gas often used in sterilization. For the purpose of the tender, the 125L Ozone Sterilizer was thoroughly analysed and favourably compared to competition. «Once again, ozone sterilization appears to be the preferred option for a Canadian hospital that wishes to comply to Environment Canada regulations, while enjoying the many benefits of a simple, efficacious and economical method for sterilization», stated Jocelyn Vézina, CEO for TSO3 Inc. As a reminder, Environment Canada has asked hospitals to reduce their release of Ethylene Oxide into the environment by 99%. For more information, please see the “Guidelines for the Reduction of Ethylene Oxide Releases from Sterilization Applications” at the following address: http://canadagazette.gc.ca/partI/2005/20051001/html/notice-e.html About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology whit high commercial potential. The Company’s first product, the 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment. In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. The 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006. TSO3 currently has more than 65 employees, about half of whom work in the sales and marketing team. The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - Source: TSO3 Inc. Information: Caroline Côté Director, Corporate Communications & IR (418) 651-0003, Ext. 237 Email: ccote@tso3.com |
© 2005-2008 TSO3. All Rights Reserved.
